targeted radiotherapy News
-
Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
Lausanne, Switzerland- March 25, 2020 - Debiopharm, a Swiss-based biopharmaceutical company announced today having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program, now called Debio 0228, which targets the CAIX (Carbonic Anhydrase 9) enzyme to fight the ...
-
ITM Executes Option to In-license Targeted Radionuclide Therapy Candidate LuCaFab (ITM-31) for the Treatment of Malignant Brain Tumors
ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced the execution of an exclusive licensing option for LuCaFab (now ITM-31), a novel Targeted Radionuclide Therapy candidate for the treatment of malignant glioblastoma. ITM-31 is a carbonic anhydrase XII (CA XII)-specific antibody Fab fragment developed by Helmholtz Munich and coupled with ITM's ...
-
CSIRO at Australia’s biggest ICT trade show – CeBIT
CeBIT, the nation’s leading trade show for ICT industries and research organisations, is on in Sydney from 24-26 May. The CSIRO stand, staffed by experts in science, engineering and commercialisation, will feature displays of the following technology: augmented reality visualisation to enable remote delivery of complicated expert services in healthcare, education and controlling ...
-
Edinburgh Molecular Imaging Closes Financing
Edinburgh Molecular Imaging Ltd, a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance new molecular targeted systemic radiotherapy agents, EMT-100 and EMT-101 to be ready for clinic development. Current investors and one new investor supported the round. EMT-100 and EMT-101 have been developed as ...
-
TAE Life Sciences Announces Installation of First Accelerator-based Neutron Beam System for Biologically Targeted Radiation Therapy at Xiamen Humanity Hospital in China
TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the successful installation of its neutron beam system at Xiamen Humanity Hospital, the most advanced accelerator-based BNCT facility in Greater China, newly built in partnership with Neuboron Medical Group. TLS’ Neutron Beam System ...
-
Neutron Therapeutics and University Hospital of Brussels Announce Their Collaboration to Offer Cancer Patients a Revolutionary New Treatment Method at Institut Jules Bordet
BOSTON & BRUSSELS--(BUSINESS WIRE)--Neutron Therapeutics, Inc (NT) and the University Hospital of Brussels (H.U.B) today announced that they have signed a Letter of Intent to place a nuBeam® suite for Boron-Neutron Capture Therapy (BNCT) at the Institut Jules Bordet (IJB), Erasmus Campus, Anderlecht. nuBeam® is the world’s safest and most powerful accelerator-based neutron ...
-
Neutron Therapeutics and University Hospital of Brussels Announce Their Collaboration to Offer Cancer Patients a Revolutionary New Treatment Method at Institut Jules Bordet
BOSTON & BRUSSELS--(BUSINESS WIRE)--Neutron Therapeutics, Inc (NT) and the University Hospital of Brussels (H.U.B) today announced that they have signed a Letter of Intent to place a nuBeam® suite for Boron-Neutron Capture Therapy (BNCT) at the Institut Jules Bordet (IJB), Erasmus Campus, Anderlecht. nuBeam® is the world’s safest and most powerful accelerator-based neutron ...
-
Neutron Therapeutics and Cosylab Announce Strategic Collaboration to Bring Boron Neutron Capture Therapy to Patients
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world’s leading provider of control systems for the planet’s most complex machines, today announced the close of a strategic collaboration and investment agreement to incorporate ...
-
GT Medical Technologies Wins Prestigious Innovator of the Year Award at the 2021 Governor`s Celebration of Innovation
GT Medical Technologies, Inc. today announced it was named a winner of the Innovator of the Year in the small company category at the 2021 Governor's Celebration of Innovation, presented live on stage by the Arizona Technology Council and the Arizona Commerce Authority on October 13. GT Medical Technologies received this accolade in recognition of GammaTile® Therapy, its Surgically Targeted ...
-
TAE Life Sciences Partners with BEC to Incorporate Specialized Robotic Patient Positioning System in its Alphabeam System for High-Precision Boron Neutron Capture Therapy
TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced a partnership with BEC GmbH (BEC) to incorporate a customized, robotic patient positioning system as part of its Alphabeam™ Neutron System for the high-precision radiation treatment of tumors. During BNCT, it is essential that the ...
-
GT Medical Technologies Announces First Patient Treated in Registry Trial of GammaTile Therapy for Brain Tumors
GT Medical Technologies, Inc., a company dedicated to improving the lives of patients with brain tumors, today announced the first patient has been enrolled into its registry trial of GammaTile®, a FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) for newly diagnosed malignant and recurrent brain tumors. The study will evaluate the safety and effectiveness of GammaTile Therapy in a ...
-
TAE Life Sciences to Sponsor Industry Expert Theater “New Era in Biologically-Targeted Radiation Therapy” at 2021 ASTRO Annual Meeting
TAE Life Sciences (TLS), a biological-targeted radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced the sponsorship of an Industry-Expert Theater session focused on advancements in BNCT at the American Society for Radiation Oncology (ASTRO) Annual Meeting, occurring October 24-27, 2021. The session, “New Era in Biologically-Targeted ...
-
Ackerman Cancer Center Celebrates 2,000 Patients Treated with Proton Therapy
Ackerman Cancer Center (ACC), the world’s first and only physician-owned proton therapy center, has reached a significant milestone in cancer care with the treatment of their 2,000th proton therapy patient. The Mevion-equipped center treated its first proton therapy patient in April of 2015 and reached its 1,000th patient milestone in October of 2018. “Congratulations to the ...
-
TAE Life Sciences Identifies Proprietary Drug Candidates to Support Boron Neutron Capture Therapy (BNCT)
Drugs being developed to expand indications for treatment and improve efficacy of BNCT for cancer treatment Only company developing comprehensive new target drug portfolio and accelerator-based neutron system TAE Life Sciences (TLS), a biological-targeting radiation therapy company developing next-generation boron neutron capture therapy (BNCT), today announced that as part of its growing ...
-
University Hospitals Is First in Cleveland To Offer GT Medical Technologies` New Targeted Therapy for Brain Tumors
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman ...
-
University Hospitals Is First in Cleveland To Offer GT Medical Technologies` New Targeted Therapy for Brain Tumors
A University Hospitals Cleveland Medical Center neurosurgeon is among the first in the region to begin offering GammaTile® Therapy, a new approach to treating brain tumors. GammaTile Therapy is an FDA-cleared, Surgically Targeted Radiation Therapy (STaRT) that is designed to delay tumor regrowth for patients with brain tumors while protecting healthy brain tissue. University Hospitals Seidman ...
-
GeneCentric Publishes New Data Comparing Predictive Immune Response Profiles in Patients Treated with Checkpoint Inhibition or IL-2
A novel RNA-based IL-2 treatment response classifier was developed as part of the study in patients with renal cell carcinoma Durham, NC, August 23, 2022 – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, announced its new publication in Cancer Research Communications that compares the immunogenomic response profiles to anti-PD-(L)1 ...
-
TAE Life Sciences and CNAO (National Center of Oncological Hadrontherapy) Announce a Research and Clinical Collaboration for the Implementation of a New Facility with Boron Neutron Capture Therapy System in Italy
TAE Life Sciences (TLS), a biologically-targeted radiation therapy company developing a breakthrough, accelerator-based boron neutron capture therapy (BNCT) system, today announced that it has entered into an agreement with National Center of Oncological Hadrontherapy (CNAO) to provide its Alphabeam™ Neutron System for the treatment of invasive, recurrent and difficult to treat cancers. ...
-
First Simulated Patient Treatment Carried Out in the First Hospital-Based BNCT Facility in Europe
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world’s leading provider of control systems for the planet’s most complex machines, today announced that Neutron Therapeutics' nuBeam® BNCT System, using Cosylab's OncologyOne ...
-
First Completion of a Full Treatment Workflow in the First European Hospital-Based BNCT Facility
BOSTON & LJUBLJANA, Slovenia--(BUSINESS WIRE)--Neutron Therapeutics, a targeted radiation therapy company developing a comprehensive solution for Boron Neutron Capture Therapy (BNCT), and Cosylab, the world's leading provider of control systems for the planet's most complex machines, today announced that they have reached their second joint milestone in the clinical commissioning of Neutron ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you